K
8.49
0.01 (0.12%)
| Previous Close | 8.48 |
| Open | 8.53 |
| Volume | 1,564,410 |
| Avg. Volume (3M) | 1,511,703 |
| Market Cap | 738,778,752 |
| Price / Sales | 9.58 |
| Price / Book | 2.60 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2026 |
| Profit Margin | -267.52% |
| Operating Margin (TTM) | -458.61% |
| Diluted EPS (TTM) | -2.09 |
| Total Debt/Equity (MRQ) | 5.31% |
| Current Ratio (MRQ) | 8.07 |
| Operating Cash Flow (TTM) | 111.23 M |
| Levered Free Cash Flow (TTM) | -95.01 M |
| Return on Assets (TTM) | -19.60% |
| Return on Equity (TTM) | -41.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Kura Oncology, Inc. | Bullish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | 0.63 |
|
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates targeting cancer signaling pathways. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.09% |
| % Held by Institutions | 93.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alethea Capital Management, Llc | 31 Dec 2025 | 1,422,682 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 371.14%) | Buy |
| Median | 30.00 (253.36%) | |
| Low | 20.00 (Leerink Partners, 135.57%) | Buy |
| Average | 30.00 (253.36%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 9.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Jan 2026 | 40.00 (371.14%) | Buy | 9.21 |
| Leerink Partners | 13 Jan 2026 | 20.00 (135.57%) | Buy | 9.21 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |